212 related articles for article (PubMed ID: 22322534)
1. The exon 3-deleted growth hormone receptor: molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions.
Filopanti M; Giavoli C; Grottoli S; Bianchi A; De Marinis L; Ghigo E; Spada A
J Endocrinol Invest; 2011 Dec; 34(11):861-8. PubMed ID: 22322534
[TBL] [Abstract][Full Text] [Related]
2. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
3. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
4. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
5. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
6. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
7. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
8. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.
Ko JM; Kim JM; Cheon CK; Kim DH; Lee DY; Cheong WY; Kim EY; Park MJ; Yoo HW
Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916
[TBL] [Abstract][Full Text] [Related]
9. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.
Andujar-Plata P; Fernandez-Rodriguez E; Quinteiro C; Casanueva FF; Bernabeu I
Pituitary; 2015 Feb; 18(1):101-7. PubMed ID: 24710993
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
Bianchi A; Mazziotti G; Tilaro L; Cimino V; Veltri F; Gaetani E; Pecorini G; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2009; 12(3):196-9. PubMed ID: 19089622
[TBL] [Abstract][Full Text] [Related]
11. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
[TBL] [Abstract][Full Text] [Related]
12. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
[TBL] [Abstract][Full Text] [Related]
13. The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.
Cinar N; Dagdelen S; Yorgun H; Canpolat U; Kabakçı G; Erbas T
Pituitary; 2015 Feb; 18(1):116-25. PubMed ID: 24706164
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
[TBL] [Abstract][Full Text] [Related]
15. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
16. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism.
Bianchi A; Giampietro A; Tartaglione L; Chiloiro S; Gentilella R; Bima C; Anile C; Olivi A; Pontecorvi A; De Marinis L
J Neuroendocrinol; 2019 Apr; 31(4):e12692. PubMed ID: 30712287
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
20. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
